Centrifugation Determines What Is in the Syringe, Not What Happens to the Patient: A Systematic Meta-Analysis of Platelet-Rich Plasma Preparation, Platelet Integrity, Cell Counts, Growth Factors and Clinical Outcomes in Regenerative Medicine

Table 9: Composition, dose and injection-number comparisons from the umbrella stream.  Leukocyte-rich versus leukocyte-poor comparisons are consistently null; platelet dose comparisons consistently favour the higher-dose arm in knee osteoarthritis. Injection-number comparisons favour repeated injection but with wide intervals.

Two patterns separate cleanly. First, the leukocyte question — the most-debated composition variable in the field — is empirically quiet: direct leukocyte-rich versus leukocyte-poor comparisons cross the null in every pooled estimate retrieved, and a published meta-regression of leukocyte content against outcome was likewise null. Second, platelet dose is not quiet. High-concentration PRP outperformed the pooled overall PRP estimate on WOMAC total at 12 months by a wide margin, and a dose-stratified review found a positive gradient across platelet-dose bands in knee osteoarthritis. A parallel analysis in rotator cuff disease found no such gradient, so the dose signal is indication-specific rather than universal.

This is the pivot of the whole analysis. The laboratory stream shows that spin architecture and cumulative dose — not g-force — determine platelet dose, with a between-protocol range of 1.47× to 9.50×. The clinical stream shows that platelet dose is the one composition variable that tracks outcome. And the reporting stream shows that only 7 of 57 trials tell us what dose they gave. The mechanism linking preparation to outcome is not missing; it is unmeasured.

Discussion

Principal findings

Four findings emerge. First, the pooled platelet concentration factor across the published record is 4.63×, not the 3–5× usually quoted, and the spread between protocols (1.47–9.50×) is larger than most clinicians assume. Second, the relative centrifugal force of an individual spin has no measurable relationship with yield across the range in clinical use (R² < 0.01 for both spins), whereas spin architecture has a large one (Hedges g = 1.20). Third, the evidence that clinically used centrifugation destroys platelets is weaker than its rhetorical prominence: the studies that measured integrity directly mostly found none, and several apparent damage findings are recovery losses that are equally consistent with mechanical entrapment. Fourth, the composition variable that tracks clinical outcome is platelet dose, not leukocyte class — and it is the variable least often reported.

Why g-force fails as a predictor

The null g-force result is not a statistical artefact of a noisy literature; it has a mechanical explanation. Sedimentation under centrifugation is governed by force multiplied by time, and by the geometry of the separation — rotor type, tube fill, plasma column height, the position from which the operator aspirates. A protocol at 200 g for 20 minutes and one at 800 g for 5 minutes deliver comparable cumulative dose and, in this dataset, comparable yield. Reporting only the g-force therefore discards most of the mechanically relevant information. The finding that cumulative g·min performed better than either spin force alone, while still explaining only about one seventh of the variance, points to the remaining share being operator technique and device geometry — the parts of the procedure that no protocol description currently captures.

The practical implication is uncomfortable for kit marketing, which usually foregrounds a proprietary speed. Two kits quoting different g-forces may produce indistinguishable products, while two operators using the same kit may not.

The lysis question, reconsidered

The 3,000 g threshold has become a citation habit. It traces to a single viability study, and while that study is methodologically sound, the condition it tested — 3,000 g sustained for 20 minutes — sits at the outer edge of clinical practice. Against it stand four independent direct measurements of platelet integrity at routine forces that found nothing: P-selectin unchanged during concentration, no CD62P difference between rotor geometries, lactate dehydrogenase unchanged at 1,600 g for 20 minutes, and no difference in activated-platelet fraction between protocols. A historical haematology protocol using 3,000 g for 20 minutes reported 86% platelet harvest without viability loss.

This does not mean centrifugation is biologically inert. Activation markers do rise at 800–1,200 g in at least one careful series, aggregation and morphological change have been documented at 1,000 g on the second spin, and electron microscopy of one double-spin system showed aggregate alteration. The honest summary is that partial, sub-lytic activation is real and force-related, while frank lysis at clinically used settings is not established. Since partial activation may release growth factors prematurely into the supernatant rather than at the treatment site, this remains clinically relevant — but it is a different mechanism from destruction, and it demands different assays.

Growth factors are the wrong reporting target

Growth factor concentrations varied by two to three orders of magnitude between studies and did not correlate significantly with platelet concentration factor. Some of that variance is biological, but much is methodological: whether the sample was activated before assay, whether platelets were lysed to release intracellular stores, which immunoassay platform was used, and whether results were normalised per volume or per million platelets. Until those choices are standardised, reported growth factor concentrations are not comparable across laboratories and should not be used to characterise a product. Platelet dose — the absolute number of platelets delivered, in billions — is measurable with a standard haematology analyser, reproducible, and directly linked in the dose-stratified clinical literature to outcome.

The reporting failure is the rate-limiting step

The most actionable finding in this analysis is not biological. 23 of 57 randomised trials (40%) provide no usable preparation detail, and only 7 state the platelet concentration factor delivered. Meta-analyses of this literature routinely report I² above 75% — in this umbrella stream, 45% of pooled estimates exceeded that threshold — and then attribute the heterogeneity to preparation differences they cannot observe. That attribution may well be correct. It is simply untestable with the data as published, and it will remain untestable however many further trials are run under current reporting norms.

Several classification frameworks already exist for this purpose, reporting platelet dose, purity, activation state and efficiency. Their existence is not the problem; their adoption is. A minimum dataset of six numbers — whole-blood platelet count, final platelet concentration, final volume, absolute platelet dose in billions, leukocyte concentration, and spin parameters including rotor type — would take a trialist minute to report and would transform the interpretability of the entire field.

Limitations

• The laboratory stream pools preparation arms from heterogeneous protocols and donor populations rather than randomised comparisons; between-arm contrasts are therefore observational and susceptible to confounding by laboratory, device and donor characteristics.
• Several studies contribute multiple arms, which introduces within-study correlation not modelled in the descriptive pooling; the between-architecture contrast was confirmed with a rank-based test to reduce sensitivity to this.
• Only 5 randomised trials reported sufficient arm-level data for participant-level pooling, so the pooled clinical effect is imprecise and not representative of the full trial literature.
• Umbrella estimates overlap substantially in their constituent trials and were deliberately not re-pooled; the distributional summary presented instead cannot be interpreted as a single effect size.
• Growth factor comparisons are limited by assay heterogeneity, and the small number of arms reporting each analyte limits the power of the correlation analyses.
• Publication and language bias were not formally assessed for the laboratory stream, where funnel-plot methods are not applicable to single-arm descriptive data.

Implications for practice and research

For clinicians, three recommendations follow from these data. Choose a double-spin or buffy-coat protocol when platelet dose matters, because architecture, not speed, drives yield. Stop selecting kits on quoted g-force. Measure and record the platelet count of the product delivered — a single analyser run — so that individual practice can be audited against the dose-response literature.

For researchers, the priority is not another placebo-controlled trial of unspecified PRP. It is dose-stratified randomisation: the same preparation system, deliberately delivering defined platelet doses, in a single indication, with product characterization reported for every participant. The dose signal already visible in the pooled literature is strong enough to justify that design and too confounded to be settled without it.

Conclusion

Centrifugation determines what is in the syringe. Spin architecture and cumulative centrifugal dose govern platelet concentration — pooled at 4.63× across the published record, ranging from 1.47× to 9.50× — while the raw g-force of any single spin does not. The widely repeated claim that clinically used centrifugation lyses platelets is not supported by direct integrity assays, although sub-lytic activation at higher forces is real. Growth factor concentrations are too assay-dependent to serve as a product descriptor. In the clinical literature, PRP outperforms its comparators more often than not, and platelet dose is the only composition variable with a consistent signal — yet 23 of 57 randomised trials do not report their preparation at all. The chain from centrifuge to patient is not broken at the biology. It is broken at the methods section, and it can be repaired with six numbers.

Declarations

Not applicable. This study analysed previously published data only.

Availability of data and materials

All extracted data rows, with their source bindings, are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

No funding.

Authors' contributions

[MHK, CAPMR] conceived and designed the study. All authors read, revised and approved the final manuscript.

References

1. Perez AG, Lichy R, Lana JF, Rodrigues AA, Luzo AC, et al. (2013) Prediction and modulation of platelet recovery by discontinuous centrifugation of whole blood for the preparation of pure platelet-rich plasma. Biores Open Access. 2(4):307-14.
2. Perez AG, Lana JF, Rodrigues AA, Luzo AC, Belangero WD, et al. (2014) Relevant aspects of centrifugation step in the preparation of platelet-rich plasma. ISRN Hematol. 2014:176060.
3. Amable PR, Carias RB, Teixeira MV, da Cruz Pacheco I, Correa do Amaral RJ, et al. (2013) Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 4(3):67.
4. Bausset O, Giraudo L, Veran J, Magalon J, Coudreuse JM, et al. (2012) Formulation and storage of platelet-rich plasma homemade product. Biores Open Access. 1(3):115-123.
5. Fitzpatrick J, Bulsara MK, McCrory PR, Richardson MD, Zheng MH. (2017) Analysis of Platelet-Rich Plasma Extraction: Variations in Platelet and Blood Components Between 4 Common Commercial Kits. Orthop J Sports Med. X5(1):2325967116675272.
6. Magalon J, Chateau AL, Bertrand B, Louis ML, Silvestre A,  et al.(2016) DEPA classification: a proposal for standardising PRP use and a retrospective application of available devices. BMJ Open Sport Exerc Med. 2(1):e000060.
7. Piao L, Piao L, Park H, Jo CH.(2017) Theoretical prediction and validation of cell recovery rates in preparing platelet-rich plasma through a centrifugation. PLoS One. X 12(11):e0187509. Available from:
8. Yin W, Qi X, Zhang Y, Sheng J, Xu ZX,  et al.(2016) Advantages of pure platelet-rich plasma compared with leukocyte- and platelet-rich plasma in promoting repair of bone defects. J Transl MedX. 14:73.
9. Roh YH, Kim W, Park KU, Oh JH.(2016) Cytokine-release kinetics of platelet-rich plasma according to various activation protocols. Bone Joint Res. 5(2):37-45.
10. Etulain J, Mena HA, Meiss RP, Frechtel G, Gutt S, et al.(2018) An optimised protocol for platelet-rich plasma preparation to improve its angiogenic and regenerative properties. Sci Rep 8(1):1513.
11. Taniguchi Y, Yoshioka T, Sugaya H, Gosho M, Aoto K, et al.(2019) Growth factor levels in leukocyte-poor platelet-rich plasma and correlations with donor age, gender, and platelets in the Japanese population. J Exp Orthop. 6(1):4.
12. Dejnek M, Witkowski J, Moreira H, Płaczkowska S, Morasiewicz P, et al.(2022)Content of blood cell components, inflammatory cytokines and growth factors in autologous platelet-rich plasma obtained by various methods. World J Orthop. 13(6):587-602.
13. Muthu S, Krishnan A, Ramanathan KR.(2022) Standardization and validation of a conventional high yield platelet-rich plasma preparation protocol. Ann Med Surg (Lond). 82:104593.
14. Machado ES, Soares FP, Yamaguchi RS, Felipone WK, Meves R,  et al.(2022) A Simple Double-Spin Closed Method for Preparing Platelet-Rich Plasma. Cureus.;14(1):e20899.
15. Carvalho A, Ferreira AF, Soares M, Santos S, Tomé P,  et al.(2024) Optimization of Platelet-Rich Plasma Preparation for Regenerative Medicine: Comparison of Different Anticoagulants and Resuspension Media. Bioengineering (Basel). 11(3):209.
16. Husak V, Povelychenko O, Maltseva V, Romanenko K, Vorontsov P, et al.(2025)Growth factor and cell content in Platelet-Rich Plasma (PRP), Leukocyte- and Platelet-Rich Plasma (L-PRP), Platelet-Rich Fibrin (PRF) in patients with long bone defects from combat injuries. BMC Musculoskelet Disord. 26(1):1106.
17. Miroshnychenko O, Chalkley RJ, Leib RD, Everts PA, Dragoo JL.(2020) Proteomic analysis of platelet-rich and platelet-poor plasma. Regen Ther. 15:226-235.
18. Huber SC, Cunha Júnior JL, Montalvão S, da Silva LQ, Paffaro AU, et al.(2016) In vitro study of the role of thrombin in platelet rich plasma (PRP) preparation: utility for gel formation and impact in growth factors release. J Stem Cells Regen Med. 12(1):2-9.
19. Kruel AVS, Ferreira M, Agostini D, Diesel CV, Queiroz M, et al.(2026) Comparative Characterization of Leukocyte-Rich Platelet-Rich Plasma (L-PRP) and Injectable Platelet-Rich Fibrin (i-PRF): A Laboratory Study. Cells. 15(10):886.
20. Garrison L, Nicks D, Nicks S, Green J, Pham H, et al.(2026)Evaluation of accuracy of platelet rich plasma preparation devices for cardiac surgery: A prospective, randomized, single blinded study. J Extra Corpor Technol. 58(2):124-127.
21. Panero AJ, Warrick AE, Nakagawa H, Andersen W, Hirahara A, et al.(2025)Comparing Biologic Factor Composition of Birth Tissue-Derived Allografts and Platelet-Rich Plasma. Cureus. 17(8):e90259.
22. Okumo T, Sato A, Izukashi K, Ohta M, Oike J, et al.(2023) Multifactorial Comparative Analysis of Platelet-Rich Plasma and Serum Prepared Using a Commercially Available Centrifugation Kit. Cureus. 15(11):e48918.
23. Menon SS, Balakrishnan B, Kurumathur Vasudevan A, Rajan Peter M, Suresh R.(2026) Effect of Reduced Centrifugation Time on Leukocyte, Platelet, and Growth Factor Levels in Platelet-Rich Fibrin (PRF) Prepared Using Low-Speed Relative Centrifugal Force (RCF): An Ex Vivo Study. Cureus. 2026;18(1):e100846.
24. Araki J, Jona M, Eto H, Aoi N, Kato H, et al.(2012) Optimized preparation method of platelet-concentrated plasma and noncoagulating platelet-derived factor concentrates: maximization of platelet concentration and removal of fibrinogen. Tissue Eng Part C Methods. 18(3):176-185.
25. Mazzocca AD, McCarthy MB, Chowaniec DM, Cote MP, Romeo AA, et al.(2012) Platelet-rich plasma differs according to preparation method and human variability. J Bone Joint Surg Am. 94(4):308-316.
26. Weibrich G, Kleis WK, Hafner G, Hitzler WE.(2002) Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg. 30(2):97-102.
27. Eppley BL, Woodell JE, Higgins J.(2004) Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. Plast Reconstr Surg. X 114(6):1502-1508.
28. Sundman EA, Cole BJ, Fortier LA.(2011) Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. X 39(10):2135-2140.
29. Jo CH, Roh YH, Kim JE, Shin S, Yoon KS.(2013) Optimizing platelet-rich plasma gel formation by varying time and gravitational forces during centrifugation. J Oral Implantol. 39(5):525-532.
30. Slichter SJ, Harker LA.(1976) Preparation and storage of platelet concentrates. I. Factors influencing the harvest of viable platelets from whole blood. Br J Haematol. 34(3):395-402.
31. Tamimi FM, Montalvo S, Tresguerres I, Blanco Jerez L.(2007) A comparative study of 2 methods for obtaining platelet-rich plasma. J Oral Maxillofac Surg. 65(6):1084-1093.
32. Oh JH, Kim W, Park KU, Roh YH.(2015) Comparison of the Cellular Composition and Cytokine-Release Kinetics of Various Platelet-Rich Plasma Preparations. Am J Sports Med. 43(12):3062-3070.
33. Kobayashi Y, Saita Y, Nishio H, Ikeda H, Takazawa Y, et al.(2016) Leukocyte concentration and composition in platelet-rich plasma (PRP) influences the growth factor and protease concentrations. J Orthop Sci. X;21(5):683-689.
34. Magalon J, Bausset O, Serratrice N, Giraudo L, Aboudou H, et al.(2014) Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model. Arthroscopy. 30(5):629-638.
35. Weibrich G, Kleis WK, Streckbein P, Moergel M, Hitzler WE, et al.(2012) Comparison of point-of-care methods for preparation of platelet concentrate (platelet-rich plasma). Int J Oral Maxillofac Implants. 27(4):762-769.
36. Ozer K, Kankaya Y, Colak O, Kocer U.(2019) The Impact of Duration and Force of Centrifugation on Platelet Content and Mass in the Preparation of Platelet-Rich Plasma. Aesthetic Plast Surg. 43(4):1078-1084.
37. Xie M, Zhao B, Teng J, Yang L, Wang Z, Xu S, et al. Effect of Fixed-Angle and Horizontal Rotor Centrifugation on Optimized Platelet-Rich Plasma Preparation. Aesthetic Plast Surg. 2025;49(17):4989-4998.
38. Croisé B, Paré A, Joly A, Louisy A, Laure B, et al.(2020) Optimized centrifugation preparation of the platelet rich plasma: Literature review. J Stomatol Oral Maxillofac Surg.121(2):150-154.
39. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. (2009) Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol.27(3):158-167.
40. Landesberg R, Roy M, Glickman RS.(2005) Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation. J Oral Maxillofac Surg. 58(3):297-300; discussion 300-1.
41. Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. (2013) Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med. 41(2):356-364.
42. Filardo G, Di Matteo B, Di Martino A, Merli ML, Cenacchi A,  et al. (2015) Platelet-Rich Plasma Intra-articular Knee Injections Show No Superiority Versus Viscosupplementation: A Randomized Controlled Trial. Am J Sports Med. 43(7):1575-1582.
43. Cole BJ, Karas V, Hussey K, Pilz K, Fortier LA. (2017) Hyaluronic Acid Versus Platelet-Rich Plasma: A Prospective, Double-Blind Randomized Controlled Trial Comparing Clinical Outcomes and Effects on Intra-articular Biology for the Treatment of Knee Osteoarthritis. Am J Sports Med. 45(2):339-346.
44. Görmeli G, Görmeli CA, Ataoglu B, Çolak C, Aslantürk O, et al. (2017)Multiple PRP injections are more effective than single injections and hyaluronic acid in knees with early osteoarthritis: a randomized, double-blind, placebo-controlled trial. Knee Surg Sports Traumatol Arthrosc.  25(3):958-965.
45. Di Martino A, Di Matteo B, Papio T, Tentoni F, Selleri F,  et al. Platelet-Rich Plasma Versus Hyaluronic Acid Injections for the Treatment of Knee Osteoarthritis: Results at 5 Years of a Double-Blind, Randomized Controlled Trial. Am J Sports Med. 2019;47(2):347-354.
46. Bennell KL, Paterson KL, Metcalf BR, Duong V, Eyles J, et al. (2021)Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA. 326(20):2021-2030. Available from: https://doi.org/10.1001/jama.2021.19415
47. Chu J, Duan W, Yu Z, Tao T, Xu J, et al. (2022) Intra-articular injections of platelet-rich plasma decrease pain and improve functional outcomes than sham saline in patients with knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 30(12):4063-4071.
48. Elksniņš-Finogejevs A, Vidal L, Peredistijs A.(2020) Intra-articular platelet-rich plasma vs corticosteroids in the treatment of moderate knee osteoarthritis: a single-center prospective randomized controlled study with a 1-year follow up. J Orthop Surg Res. 15(1):257.
49. Raeissadat SA, Rayegani SM, Hassanabadi H, Fathi M, Ghorbani E, et al. (2015) Knee Osteoarthritis Injection Choices: Platelet- Rich Plasma (PRP) Versus Hyaluronic Acid (A one-year randomized clinical trial). Clin Med Insights Arthritis Musculoskelet Disord. 8:1-8.
50. Rayegani SM, Raeissadat SA, Taheri MS, Babaee M, Bahrami MH, et al. (2014) Does intra articular platelet rich plasma injection improve function, pain and quality of life in patients with osteoarthritis of the knee? A randomized clinical trial. Orthop Rev (Pavia). 6(3):5405.
51. Duymus TM, Mutlu S, Dernek B, Komur B, Aydogmus S, et al. (2017)Choice of intra-articular injection in treatment of knee osteoarthritis: platelet-rich plasma, hyaluronic acid or ozone options. Knee Surg Sports Traumatol Arthrosc. 25(2):485-492.
52. Lisi C, Perotti C, Scudeller L, Sammarchi L, Dametti F,  et al.(2018) Treatment of knee osteoarthritis: platelet-derived growth factors vs. hyaluronic acid. A randomized controlled trial. Clin Rehabil. 32(3):330-339.
53. Louis ML, Magalon J, Jouve E, Bornet CE, Mattei JC, Chagnaud C, et al. Growth Factors Levels Determine Efficacy of Platelets Rich Plasma Injection in Knee Osteoarthritis: A Randomized Double Blind Noninferiority Trial Compared With Viscosupplementation. Arthroscopy. 34(5):1530-1540.e2.
54. Buendía-López D, Medina-Quirós M, Fernández-Villacañas Marín MÁ. (2018) Clinical and radiographic comparison of a single LP-PRP injection, a single hyaluronic acid injection and daily NSAID administration with a 52-week follow-up: a randomized controlled trial. J Orthop Traumatol. 19(1):3.
55. Su K, Bai Y, Wang J, Zhang H, Liu H, et al. (2018)Comparison of hyaluronic acid and PRP intra-articular injection with combined intra-articular and intraosseous PRP injections to treat patients with knee osteoarthritis. Clin Rheumatol. 37(5):1341-1350.
56. Huang Y, Liu X, Xu X, Liu J. (2019) Intra-articular injections of platelet-rich plasma, hyaluronic acid or corticosteroids for knee osteoarthritis: A prospective randomized controlled study. Orthopade. 48(3):239-247.
57. Lin KY, Yang CC, Hsu CJ, Yeh ML, Renn JH. (2019) Intra-articular Injection of Platelet-Rich Plasma Is Superior to Hyaluronic Acid or Saline Solution in the Treatment of Mild to Moderate Knee Osteoarthritis: A Randomized, Double-Blind, Triple-Parallel, Placebo-Controlled Clinical Trial. Arthroscopy. 35(1):106-117.
58. Yurtbay A, Say F, Çinka H, Ersoy A.(2022) Multiple platelet-rich plasma injections are superior to single PRP injections or saline in osteoarthritis of the knee: the 2-year results of a randomized, double-blind, placebo-controlled clinical trial. Arch Orthop Trauma Surg. 142(10):2755-2768.
59. Smith PA. Intra-articular Autologous Conditioned Plasma Injections Provide Safe and Efficacious Treatment for Knee Osteoarthritis: An FDA-Sanctioned, Randomized, Double-blind, Placebo-controlled Clinical Trial. Am J Sports Med.44(4):884-891.
60. Cerza F, Carnì S, Carcangiu A, Di Vavo I, Schiavilla V, et al. (2012) Comparison between hyaluronic acid and platelet-rich plasma, intra-articular infiltration in the treatment of gonarthrosis. Am J Sports Med. 40(12):2822-2827.
61. Spaková T, Rosocha J, Lacko M, Harvanová D, Gharaibeh A. (2012) Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil. 91(5):411-417.
62. Paterson KL, Nicholls M, Bennell KL, Bates D. (2016) Intra-articular injection of photo-activated platelet-rich plasma in patients with knee osteoarthritis: a double-blind, randomized controlled pilot study. BMC Musculoskelet Disord. 17:67.
63. Forogh B, Mianehsaz E, Shoaee S, Ahadi T, Raissi GR, et al. (2016)Effect of single injection of platelet-rich plasma in comparison with corticosteroid on knee osteoarthritis: a double-blind randomized clinical trial. J Sports Med Phys Fitness. 56(7-8):901-908.
64. Montañez-Heredia E, Irízar S, Huertas PJ, Otero E, Del Valle M, et al. (2016) Intra-Articular Injections of Platelet-Rich Plasma versus Hyaluronic Acid in the Treatment of Osteoarthritic Knee Pain: A Randomized Clinical Trial in the Context of the Spanish National Health Care System. Int J Mol Sci. 17(7):E1064.
65. Filardo G, Kon E, Di Martino A, Di Matteo B, Merli ML, et al. (2012) Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord. 13:229.
66. Di Martino A, Boffa A, Andriolo L, Romandini I, Altamura SA,  et al. (2012)  Leukocyte-Rich versus Leukocyte-Poor Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Double-Blind Randomized Trial. Am J Sports Med. 50(3):609-617.
67. Vaquerizo V, Plasencia MÁ, Arribas I, Seijas R, Padilla S,  et al. (2013) Comparison of intra-articular injections of plasma rich in growth factors (PRGF-Endoret) versus Durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: a randomized controlled trial. Arthroscopy.  29(10):1635-1643.
68. Mishra AK, Skrepnik NV, Edwards SG, Jones GL, Sampson S,  et al. (2014) Efficacy of platelet-rich plasma for chronic tennis elbow: a double-blind, prospective, multicenter, randomized controlled trial of 230 patients. Am J Sports Med. 42(2):463-471.
69. Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. (2010) Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med. 38(2):255-262.
70. Gosens T, Peerbooms JC, van Laar W, den Oudsten BL. (2011) Ongoing positive effect of platelet-rich plasma versus corticosteroid injection in lateral epicondylitis: a double-blind randomized controlled trial with 2-year follow-up. Am J Sports Med.  39(6):1200-1208.
71. Krogh TP, Fredberg U, Stengaard-Pedersen K, Christensen R, Jensen P, et al. (2013) Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial. Am J Sports Med.  41(3):625-635.
72. Behera P, Dhillon M, Aggarwal S, Marwaha N, Prakash M. (2016) Leukocyte-poor platelet-rich plasma versus bupivacaine for recalcitrant lateral epicondylar tendinopathy. J Orthop Surg (Hong Kong). 2015;23(1):6-10.
73. Palacio EP, Schiavetti RR, Kanematsu M, Ikeda TM, Mizobuchi RR, Galbiatti JA. Effects of platelet-rich plasma on lateral epicondylitis of the elbow: prospective randomized controlled trial. Rev Bras Ortop. 51(1):90-95.
74. Linnanmäki L, Kanto K, Karjalainen T, Leppänen OV, Lehtinen J. (2020) Platelet-rich Plasma or Autologous Blood Do Not Reduce Pain or Improve Function in Patients with Lateral Epicondylitis: A Randomized Controlled Trial. Clin Orthop Relat Res.478(8):1892-1900.
75. Randelli P, Arrigoni P, Ragone V, Aliprandi A, Cabitza P. (2011) Platelet rich plasma in arthroscopic rotator cuff repair: a prospective RCT study, 2-year follow-up. J Shoulder Elbow Surg.  20(4):518-528.
76. Rha DW, Park GY, Kim YK, Kim MT, Lee SC. (2013) Comparison of the therapeutic effects of ultrasound-guided platelet-rich plasma injection and dry needling in rotator cuff disease: a randomized controlled trial. Clin Rehabil.  27(2):113-122.
77. Kesikburun S, Tan AK, Yilmaz B, Yaşar E, Yazicioğlu K. (2013) Platelet-rich plasma injections in the treatment of chronic rotator cuff tendinopathy: a randomized controlled trial with 1-year follow-up. Am J Sports Med. 41(11):2609-2616.
78. Schwitzguebel AJ, Kolo FC, Tirefort J, Kourhani A, Nowak A, et al. (2019) Efficacy of Platelet-Rich Plasma for the Treatment of Interstitial Supraspinatus Tears: A Double-Blinded, Randomized Controlled Trial. Am J Sports Med.  47(8):1885-1892.
79. Pandey V, Bandi A, Madi S, Agarwal L, Acharya KK, et al. (2016) Does application of moderately concentrated platelet-rich plasma improve clinical and structural outcome after arthroscopic repair of medium-sized to large rotator cuff tear? A randomized controlled trial. J Shoulder Elbow Surg. 25(8):1312-1322.
80. Snow M, Hussain F, Pagkalos J, Kowalski T, Green M,  et al. (2020) The Effect of Delayed Injection of Leukocyte-Rich Platelet-Rich Plasma Following Rotator Cuff Repair on Patient Function: A Randomized Double-Blind Controlled Trial. Arthroscopy. 36(3):648-657.
81. Cai YU, Sun Z, Liao B, Song Z, Xiao T, et al. (2019)Sodium Hyaluronate and Platelet-Rich Plasma for Partial-Thickness Rotator Cuff Tears. Med Sci Sports Exerc. 51(2):227-233.
82. de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, Verhaar JA, et al. (2010) Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA. 303(2):144-149.
83. Monto RR. (2014) Platelet-rich plasma efficacy versus corticosteroid injection treatment for chronic severe plantar fasciitis. Foot Ankle Int. 35(4):313-318.
84. Mahindra P, Yamin M, Selhi HS, Singla S, Soni A. (2016) Chronic Plantar Fasciitis: Effect of Platelet-Rich Plasma, Corticosteroid, and Placebo. Orthopedics.  39(2):e285-9.
85. Peerbooms JC, Lodder P, den Oudsten BL, Doorgeest K, Schuller HM, et al.(2019) Positive Effect of Platelet-Rich Plasma on Pain in Plantar Fasciitis: A Double-Blind Multicenter Randomized Controlled Trial. Am J Sports Med.  47(13):3238-3246.
86. Acosta-Olivo C, Elizondo-Rodriguez J, Lopez-Cavazos R, Vilchez-Cavazos F, Simental-Mendia M, et al. (2017) Plantar Fasciitis-A Comparison of Treatment with Intralesional Steroids versus Platelet-Rich Plasma A Randomized, Blinded Study. J Am Podiatr Med Assoc. 107(6):490-496.
87. Kearney RS, Ji C, Warwick J, Parsons N, Brown J, et al. (2021) Effect of Platelet-Rich Plasma Injection vs Sham Injection on Tendon Dysfunction in Patients With Chronic Midportion Achilles Tendinopathy: A Randomized Clinical Trial. JAMA. 326(2):137-144.
88. Boesen AP, Hansen R, Boesen MI, Malliaras P, Langberg H. (2017) Effect of High-Volume Injection, Platelet-Rich Plasma, and Sham Treatment in Chronic Midportion Achilles Tendinopathy: A Randomized Double-Blinded Prospective Study. Am J Sports Med. 45(9):2034-2043.
89. Kearney RS, Parsons N, Costa ML. (2013) Achilles tendinopathy management: A pilot randomised controlled trial comparing platelet-richplasma injection with an eccentric loading programme. Bone Joint Res. 2(10):227-232.
90. Driver VR, Hanft J, Fylling CP, Beriou JM. (2006) Autologel Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage. x52(6):68-70, 72, 74 passim.
91. Game F, Jeffcoate W, Tarnow L, Jacobsen JL, Whitham DJ, et al. (2018) LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. Lancet Diabetes Endocrinol.  6(11):870-878.
92. Li L, Chen D, Wang C, Yuan N, Wang Y, et al. (2015) Autologous platelet-rich gel for treatment of diabetic chronic refractory cutaneous ulcers: A prospective, randomized clinical trial. Wound Repair Regen. X23(4):495-505.
93. Saad Setta H, Elshahat A, Elsherbiny K, Massoud K, Safe I. (2011) Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: a comparative study. Int Wound J. 8(3):307-312.
94. Kakagia DD, Kazakos KJ, Xarchas KC, Karanikas M, Georgiadis GS, et al. (2007) Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. J Diabetes Complications. 21(6):387-391.
95. Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, et al. (2015)The Effect of Platelet-Rich Plasma in Hair Regrowth: A Randomized Placebo-Controlled Trial. Stem Cells Transl Med. 4(11):1317-1323.
96. Alves R, Grimalt R. Randomized Placebo-Controlled, Double-Blind. (2006) Half-Head Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia. Dermatol Surg.  42(4):491-497.
97. Gkini MA, Kouskoukis AE, Tripsianis G, Rigopoulos D, Kouskoukis K. (2014) Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J Cutan Aesthet Surg. 7(4):213-219.
98. Han Y, Huang H, Pan J, Lin J, Zeng L, et al. (2019) Meta-analysis Comparing Platelet-Rich Plasma vs Hyaluronic Acid Injection in Patients with Knee Osteoarthritis. Pain Med. 20(7):1418-1429.
99. McLarnon M, Heron N. (2021) Intra-articular platelet-rich plasma injections versus intra-articular corticosteroid injections for symptomatic management of knee osteoarthritis: systematic review and meta-analysis. BMC Musculoskelet Disord. 2021;22(1):550.
100. Bensa A, Previtali D, Sangiorgio A, Boffa A, Salerno M, (2025)PRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration: A Meta-analysis of Randomized Controlled Trials. Am J Sports Med. 53(3):745-754.
101. Xu B, Huang X, Su X, Fu Y, Feng S,  et al. (2026) Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis. J Orthop Surg Res. 21(1):222.
102. Berrigan W, Tao F, Kopcow J, Park AL, Allen I, et al.(2024) The Effect of Platelet Dose on Outcomes after Platelet Rich Plasma Injections for Musculoskeletal Conditions: A Systematic Review and Meta-Analysis. Curr Rev Musculoskelet Med. 17(12):570-588.
103. Nie LY, Zhao K, Ruan J, Xue J. (2021) Effectiveness of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Clinical Trials. Orthop J Sports Med. 9(3):2325967120973284.
104. Peng YN, Chen JL, Hsu CC, Chen CPC, Suputtitada A. (2022) Intra-Articular Leukocyte-Rich Platelet-Rich Plasma versus Intra-Articular Hyaluronic Acid in the Treatment of Knee Osteoarthritis: A Meta-Analysis of 14 Randomized Controlled Trials. Pharmaceuticals (Basel). 15(8):974.
105. Vilchez-Cavazos F, Millán-Alanís JM, Blázquez-Saldaña J, Álvarez-Villalobos N, Peña-Martínez VM, et al. (2019) Comparison of the Clinical Effectiveness of Single Versus Multiple Injections of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-analysis. Orthop J Sports Med. 7(12):2325967119887116.
106. Zhang Q, Liu T, Gu Y, Gao Y, Ni J. (2022) Efficacy and safety of platelet-rich plasma combined with hyaluronic acid versus platelet-rich plasma alone for knee osteoarthritis: a systematic review and meta-analysis. J Orthop Surg Res. 17(1):499.
107. Dai WL, Zhou AG, Zhang H, Zhang J. (2017) Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials. Arthroscopy. 33(3):659-670.e1.
108. Xu Z, Luo J, Huang X, Wang B, Zhang J, et al. (2017) Efficacy of Platelet-Rich Plasma in Pain and Self-Report Function in Knee Osteoarthritis: A Best-Evidence Synthesis. Am J Phys Med Rehabil.  96(11):793-800.
109. Zhao D, Pan JK, Yang WY, Han YH, Zeng LF,  et al. (2021) Intra-Articular Injections of Platelet-Rich Plasma, Adipose Mesenchymal Stem Cells, and Bone Marrow Mesenchymal Stem Cells Associated With Better Outcomes Than Hyaluronic Acid and Saline in Knee Osteoarthritis: A Systematic Review and Network Meta-analysis. Arthroscopy. 2021;
110. -Carreño T, Lozano-Paniagua D, Nievas-Soriano BJ, Murillo-Cancho AF, Gázquez-Aguilera EM, et al. (2026) Efficacy and Safety of Platelet-Rich Plasma in Knee Osteoarthritis: Umbrella Meta-Analysis Based on Clinical Evidence, Methodological Quality and Therapeutic Positioning. Clin Pract.  16(4):75.
111. Arirachakaran A, Sukthuayat A, Sisayanarane T, Laoratanavoraphong S, Kanchanatawan W, et al. (2016) Platelet-rich plasma versus autologous blood versus steroid injection in lateral epicondylitis: systematic review and network meta-analysis. J Orthop Traumatol.  17(2):101-112.
112. Li A, Wang H, Yu Z, Zhang G, Feng S, et al. (2019) Platelet-rich plasma vs corticosteroids for elbow epicondylitis: A systematic review and meta-analysis. Medicine (Baltimore). 98(51):e18358.
113. Maroun R, Daher M, Boufadel P, Lopez R, Khan AZ, et al. (2025) Platelet rich plasma versus corticosteroids for lateral epicondylitis: a meta-analysis of randomized clinical trials. Clin Shoulder Elb. 28(1):40-48.
114. Simental-Mendía M, Vilchez-Cavazos F, Álvarez-Villalobos N, Blázquez-Saldaña J, Peña-Martínez V, et al. (2022) Clinical efficacy of platelet-rich plasma in the treatment of lateral epicondylitis: a systematic review and meta-analysis of randomized placebo-controlled clinical trials. Clin Rheumatol. 39(8):2255-2265.
115. Chen XT, Fang W, Jones IA, Heckmann ND, Park C, et al. (2021) The Efficacy of Platelet-Rich Plasma for Improving Pain and Function in Lateral Epicondylitis: A Systematic Review and Meta-analysis with Risk-of-Bias Assessment. Arthroscopy. 37(9):2937-2952.
116. Xu Y, Lin W, Qi Z, Yan Z, Yan, et al. (2026) Time-Dependent Efficacy and Safety of Percutaneous Treatments for Lateral Epicondylitis: A Systematic Review and Network Meta-Analysis. J Pain Res. 19:604185.
117. Ye Z, Yuan Y, Kuang G, Qiu L, Tan X, Wen Z, et al. Platelet-rich plasma and corticosteroid injection for tendinopathy: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2025;26(1):339.
118. Chen X, Jones IA, Park C, Vangsness CT. (2018) The Efficacy of Platelet-Rich Plasma on Tendon and Ligament Healing: A Systematic Review and Meta-analysis With Bias Assessment. Am J Sports Med. 46(8):2020-2032.
119. Chen X, Jones IA, Togashi R, Park C, Vangsness CT. (2020)  Use of Platelet-Rich Plasma for the Improvement of Pain and Function in Rotator Cuff Tears: A Systematic Review and Meta-analysis With Bias Assessment. Am J Sports Med. 48(8):2028-2041.
120. Dunivan Q, Allen M, Caplan BE, Cole BJ. (2026) Leukocyte-poor platelet-rich plasma reduces retear risk after arthroscopic rotator cuff repair: a meta-analysis with mechanistic and economic evaluation. J Shoulder Elbow Surg. 35(8):2037-2049.
121. Hurley ET, Shimozono Y, Hannon CP, Smyth NA, Murawski CD, et al. (2020)Platelet-Rich Plasma Versus Corticosteroids for Plantar Fasciitis: A Systematic Review of Randomized Controlled Trials. Orthop J Sports Med. 8(4):2325967120915704.
122. Ling Y, Wang S. (2018) Effects of platelet-rich plasma in the treatment of plantar fasciitis: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(37):e12110.
123. Yang WY, Han YH, Cao XW, Pan JK, Zeng LF, et al. (2017) Platelet-rich plasma as a treatment for plantar fasciitis: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 96(44):e8475.
124. Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, Expósito JA, Bolíbar I, et al. (2016) Autologous platelet-rich plasma for treating chronic wounds. Cochrane Database Syst Rev. (5):CD006899.
125. Del Pino-Sedeño T, Trujillo-Martín MM, Andia I, Aragón-Sánchez J, Herrera-Ramos E, et al. (2019) Platelet-rich plasma for the treatment of diabetic foot ulcers: A meta-analysis. Wound Repair Regen. 27(2):170-182.
126. Hu Z, Qu S, Zhang J, Cao X, Wang P, et al. (2019) Efficacy and Safety of Platelet-Rich Plasma for Patients with Diabetic Ulcers: A Systematic Review and Meta-analysis. Adv Wound Care (New Rochelle). 8(7):298-308.
127. Qu W, Wang Z, Hunt C, Morrow AS, Urtecho M, et al. (2021) The Effectiveness and Safety of Platelet-Rich Plasma for Chronic Wounds: A Systematic Review and Meta-analysis. Mayo Clin Proc. 96(9):2407-2417.
128. Qu S, Hu Z, Zhang Y, Wang P, Li S, et al. (2022) Clinical Studies on Platelet-Rich Plasma Therapy for Chronic Cutaneous Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Wound Care (New Rochelle).11(2):56-69.
129. Xia Y, Zhao J, Xie J, Lv Y, Cao DS. (2019) The Efficacy of Platelet-Rich Plasma Dressing for Chronic Nonhealing Ulcers: A Meta-Analysis of 15 Randomized Controlled Trials. Plast Reconstr Surg. 144(6):1463-1474.
130. Hu Z, Wang S, Yang H, Xv H, Shan B, et al. (2024) Efficacy and safety of platelet-rich plasma in the treatment of venous ulcers: A systematic review and meta-analysis of randomized controlled trials. Int Wound J. 21(2):e14736.
131. Guan X, Zhu G, Jiang H, Wang B, Cheng J. (2026) Comparative efficacy of advanced therapeutic modalities for diabetic foot ulcers: a systematic review and meta-analysis including NPWT, stem cells, ESWT, and bioengineered treatments. Front Bioeng Biotechnol. 14:1792670.
132. Giordano S, Romeo M, di Summa P, Salval A, Lankinen P. (2018) A Meta-analysis On Evidence Of Platelet-rich Plasma for Androgenetic Alopecia. Int J Trichology. 10(1):1-10.
133. Gupta AK, Cole J, Deutsch DP, Everts PA, Niedbalski RP, et al. (2019) Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia. Dermatol Surg. 45(10):1262-1273.
134. Anitua E, Padilla S, Prado R, Tierno R, Hamdan Alkhraisat M.(2026) Influence of platelet-rich plasma composition on pain and functional performance in knee osteoarthritis: a systematic review and network meta-analysis. Knee Surg Relat Res. X 38(1):17.
135. Martín-Vega M, Gómez-Carrión Á, Zaragoza-García I, Ortuño-Soriano I, Marcelino-Argemi A, et al. Leukocyte-rich versus leukocyte-poor platelet-rich plasma for Osteoarthritis: A systematic review. Regen Ther. 31:101078.
136. Lim JJ, Stepaniuk EA, Belk JW, Keeter C, Oeding JF,  et al.(2026) Platelet Concentration Does Not Influence Clinical Efficacy and Retear Rates of Rotator Cuff Repair With Platelet-Rich Plasma: A Systematic Review and Meta-analysis With Meta-Regression. Am J Sports Med. 54(10):2597-2609.
137. Hurley ET, Colasanti CA, Anil U, Luthringer TA, Alaia MJ,   et al. (2021) The Effect of Platelet-Rich Plasma Leukocyte Concentration on Arthroscopic Rotator Cuff Repair: A Network Meta-analysis of Randomized Controlled Trials. Am J Sports Med. 49(9):2528-2535.
138. Houck DA, Kraeutler MJ, Thornton LB, McCarty EC, Bravman JT, et al. (2019) Treatment of Lateral Epicondylitis With Autologous Blood, Platelet-Rich Plasma, or Corticosteroid Injections: A Systematic Review of Overlapping Meta-analyses. Orthop J Sports Med. 7(3):2325967119831052.
139. Ali Elsiddig Ahmed E, Muharib R Alruwaili K, Alruwaili AH, Talal M Alruwaili A, Ahmed S Aljudia H, et al. (2025) Efficacy of Platelet-Rich Plasma in Treatment of Achilles Tendinopathy: Systematic Review and Meta-Analysis. Cureus. X 17(2):e79692.
140. Gupta AK, Gupta AK, Bamimore M. (2022) Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. X 21(9):943-952.
141. Belk JW, Kraeutler MJ, Houck DA, Goodrich JA, Dragoo JL, et al. (2021) Platelet-Rich Plasma Versus Hyaluronic Acid for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Sports Med. 49(1):249-260.
142. Belk JW, Lim JJ, Keeter C, McCulloch PC, Houck DA,  et al. (2023) Patients With Knee Osteoarthritis Who Receive Platelet-Rich Plasma or Bone Marrow Aspirate Concentrate Injections Have Better Outcomes Than Patients Who Receive Hyaluronic Acid: Systematic Review and Meta-analysis. Arthroscopy. 39(7):1714-1734.
143. Costa LAV, Lenza M, Irrgang JJ, Fu FH, Ferretti M. (2023) How Does Platelet-Rich Plasma Compare Clinically to Other Therapies in the Treatment of Knee Osteoarthritis? A Systematic Review and Meta-analysis. Am J Sports Med. 51(4):1074-1086.
144. Hohmann E, Tetsworth K, Glatt V. (2020) Is platelet-rich plasma effective for the treatment of knee osteoarthritis? A systematic review and meta-analysis of level 1 and 2 randomized controlled trials. Eur J Orthop Surg Traumatol. 30(6):955-967.
145. Anil U, Markus DH, Hurley ET, Manjunath AK, Alaia MJ, Campbell KA, et al. The efficacy of intra-articular injections in the treatment of knee osteoarthritis: A network meta-analysis of randomized controlled trials. Knee. 32:173-182.
146. Migliorini F, Driessen A, Quack V, Sippel N, Cooper B,  et al. (2021) Comparison between intra-articular infiltrations of placebo, steroids, hyaluronic and PRP for knee osteoarthritis: a Bayesian network meta-analysis. Arch Orthop Trauma Surg. X 141(9):1473-1490.
147. Singh H, Knapik DM, Polce EM, Eikani CK, Bjornstad AH,  et al. (2022) Relative Efficacy of Intra-articular Injections in the Treatment of Knee Osteoarthritis: A Systematic Review and Network Meta-analysis. Am J Sports Med. 50(11):3140-3148.
148. Filardo G, Previtali D, Napoli F, Candrian C, Zaffagnini S, et al. (2021)PRP Injections for the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. Cartilage. 2021;13(1_suppl):364S-375S.
149. Chen Z, Wang C, You D, Zhao S, Zhu Z, et al. (2020) Platelet-rich plasma versus hyaluronic acid in the treatment of knee osteoarthritis: A meta-analysis. Medicine (Baltimore). 99(11):e19388.
150. Hurley ET, Lim Fat D, Moran CJ, Mullett H. 2019)The Efficacy of Platelet-Rich Plasma and Platelet-Rich Fibrin in Arthroscopic Rotator Cuff Repair: A Meta-analysis of Randomized Controlled Trials. Am J Sports Med.47(3):753-761.
151. Assi A, Hamyeh A, Mohanna R, Boutros M, Boueri W, et al. (2026) Platelet-rich plasma vs. placebo injections in achilles tendinopathy: A systematic review and meta-analysis of randomized controlled trials. J Foot Ankle Surg. X 65(4):139.e1-139.e5
152. Chen YJ, Wu YC, Tu YK, Cheng JW, Tsai WC, et al. (2019) Autologous Blood-Derived Products Compared With Corticosteroids for Treatment of Plantar Fasciopathy: A Systematic Review and Meta-Analysis. Am J Phys Med Rehabil. 98(5):343-352.
153. Xu Q, Chen J, Cheng L. (2019) Comparison of platelet rich plasma and corticosteroids in the management of lateral epicondylitis: A meta-analysis of randomized controlled trials. Int J Surg. 67:37-46.
154. Antunes Júnior CR, Santos RSS, Barreto ESR, Azevedo GN, Lima EBS, et al. (2026) Platelet-Rich Plasma Does Not Improve Pain or Function in Patients With Lateral Epicondylitis as Compared With Placebo: A Meta-analysis of Randomized Clinical Trials. Am J Sports Med. 54(5):1247-1257.
155.  Evans AG, Mwangi JM, Pope RW, Ivanic MG, Botros MA, et al. (2022) Platelet-rich plasma as a therapy for androgenic alopecia: a systematic review and meta-analysis. J Dermatolog Treat. 33(1):498-511.
156.  Nakagawa HF, Kim J, Rabinowitz J, Sussman WI. (2026)  Assessment of adverse events and safety associated with intra-articular platelet-rich plasma injections compared to other injectates for knee osteoarthritis: A systematic review and meta-analysis. PM R.
157.  Rayo-Martín R, Rayo-Rosado R, Rayo-Pérez AM, Sánchez-Morilla S, et al. (2025) Comparison of PRP Injections Versus Corticosteroid Injections in Plantar Fasciitis: Systematic Review and Meta-analysis. Foot Ankle Spec. 19386400251363002.